The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Emcitate (tiratricol), developed by Egetis Therapeutics, for the treatment of MCT8 deficiency. This positive development has led Handelsbanken to raise its three-year target price for Egetis Therapeutics to SEK 16.9, reiterating its 'Buy' recommendation.
Financial Projections Surge
Handelsbanken's analysis indicates strong confidence in Emcitate's market success. "We now assess that it is virtually certain that Emcitate will be successful in Europe," the bank stated. This optimism extends to potential approvals in other key markets, with Handelsbanken estimating a 70-80% probability of approval in both Japan and the US.
The financial outlook for Egetis Therapeutics reflects this anticipated success. Handelsbanken projects a substantial increase in revenues, from SEK 50 million in 2024 to approximately SEK 450 million in 2025 and SEK 1.4 billion in 2026. This growth is directly attributed to the expected market penetration of Emcitate following its approval and launch.
Market Response
Following the announcement, Egetis Therapeutics' share price experienced a notable increase. During Monday's trading, the share price rose by 4.8 percent to SEK 6.83, reflecting investor confidence in the company's prospects.
MCT8 Deficiency and Tiratricol
MCT8 deficiency, also known as Allan-Herndon-Dudley syndrome, is a rare X-linked genetic disorder that affects the transport of thyroid hormones into the brain. This can lead to severe neurological impairment and developmental delays. Tiratricol, the active ingredient in Emcitate, is a thyroid hormone analogue that can bypass the defective MCT8 transporter, providing thyroid hormone to the brain and potentially mitigating the effects of the deficiency.
